Slide 1: NovaSeq X
NovaSeq X Illumina continues to lead the genomics industry with the latest and most innovative sequencing technology on-market. First announced at the Illumina Genomics Forum last September, Illumina launched the revolutionary NovaSeq X Series – the most powerful, most sustainable, and most cost-eff
Slide 2: Galleri Test
GalleriTM Test GRAIL’s Galleri is among the most promising new tools in the fight against cancer and has enjoyed the fastest first-year revenue ramp of any cancer screening test. To date, more than 60,000 Galleri tests have been ordered and have impacted the lives of patients who have had the opport
Slide 3: GRAIL as an example of Illumina's innovation strategy
GRAIL, a healthcare company focused on life-saving early detection of multiple cancers, has tremendous long-term value creation potential and is a great example of Illumina’s innovation strategy. GRAIL offers the only commercially available multi-cancer early detection test, Galleri, which is capabl
Slide 4: Galleri has Strong Demand from Consumers, Physicians, Health Systems and Payors
Galleri has Strong Demand from Consumers, Physicians, Health Systems and Payors Fastest first-year revenue ramp in cancer screening test history >60,000 Galleri tests >60 Partnerships with health systems, employers, etc. >4,500 Physicians 97.1% Satisfaction rate Progress toward reimbursement FDA 201
Slide 5: Presentations
Presentations Investor Presentation April 27, 2023 Investor Presentation April 13, 2023
Slide 6: Forward-Looking Statement
Forward-Looking Statement This communication contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding mandates, the future, business plans and other statements that are not historical in nature. These statements
Slide 7: Additional Information and Where to Find It
Additional Information and Where to Find It Illumina has filed with the SEC a definitive proxy statement on Schedule 14A, containing a form of WHITE proxy card, with respect to its solicitation of proxies for Illumina’s 2023 Annual Meeting of Stockholders. INVESTORS AND SECURITY HOLDERS ARE URGED TO